Summary
Global Markets Direct’s, ‘Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2016’, provides an overview of the Metastatic Adenocarcinoma of The Pancreas pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas
- The report reviews pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Adenocarcinoma of The Pancreas therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Adenocarcinoma of The Pancreas therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Aduro BioTech, Inc.
Array BioPharma Inc.
Axcentua Pharmaceuticals AB
Berg LLC
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
CTI BioPharma Corp.
CytRx Corporation
Eleison Pharmaceuticals LLC
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Incyte Corporation
Merrimack Pharmaceuticals, Inc.
NewLink Genetics Corporation
Novartis AG
Oncolytics Biotech Inc.
Pfizer Inc.
Phoenix Biotechnology, Inc.
Plexxikon Inc.
Sanofi
Targovax AS
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Adenocarcinoma of The Pancreas Overview 10
Therapeutics Development 11
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview 11
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis 12
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies 13
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes 15
Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies 19
Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes 21
Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development 22
AbbVie Inc. 22
Aduro BioTech, Inc. 23
Array BioPharma Inc. 24
Axcentua Pharmaceuticals AB 25
Berg LLC 26
Boehringer Ingelheim GmbH 27
Boston Biomedical, Inc. 28
CTI BioPharma Corp. 29
CytRx Corporation 30
Eleison Pharmaceuticals LLC 31
Gilead Sciences, Inc. 32
GlaxoSmithKline Plc 33
Incyte Corporation 34
Merrimack Pharmaceuticals, Inc. 35
NewLink Genetics Corporation 36
Novartis AG 37
Oncolytics Biotech Inc. 38
Pfizer Inc. 39
Phoenix Biotechnology, Inc. 40
Plexxikon Inc. 41
Sanofi 42
Targovax AS 43
Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Target 45
Assessment by Mechanism of Action 48
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
aldoxorubicin hydrochloride - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AXP-10711 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BI-853520 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
binimetinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cellular Immunotherapy for Cancer - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ceritinib - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CRS-207 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
glufosfamide - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
GS-5745 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
GSK-2256098 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
ibrutinib - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
INCB-52793 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
indoximod - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
irinotecan hydrochloride - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
LGK-974 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
MesoCART - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
napabucasin - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
paclitaxel - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
palbociclib - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
PBI-05204 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
pelareorep - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
plerixafor - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
PLX-7486 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
PRI-724 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
ribociclib - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
SGT-53 - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
sonidegib phosphate - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
TG-01 - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
tosedostat - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
ubidecarenone - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
ulixertinib - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
Vaccine for Oncology - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
Metastatic Adenocarcinoma of The Pancreas - Recent Pipeline Updates 141
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects 219
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products 220
Metastatic Adenocarcinoma of The Pancreas - Product Development Milestones 221
Featured News & Press Releases 221
Jan 25, 2016: Boston Biomedical’s Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium 221
Jan 07, 2016: Baxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission 222
Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer 223
Appendix 224
Methodology 224
Coverage 224
Secondary Research 224
Primary Research 224
Expert Panel Validation 224
Contact Us 224
Disclaimer 225
List of Tables
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H1 2016 11
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Metastatic Adenocarcinoma of The Pancreas - Pipeline by AbbVie Inc., H1 2016 22
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H1 2016 23
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Array BioPharma Inc., H1 2016 24
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H1 2016 25
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Berg LLC, H1 2016 26
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H1 2016 27
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H1 2016 28
Metastatic Adenocarcinoma of The Pancreas - Pipeline by CTI BioPharma Corp., H1 2016 29
Metastatic Adenocarcinoma of The Pancreas - Pipeline by CytRx Corporation, H1 2016 30
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals LLC, H1 2016 31
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H1 2016 32
Metastatic Adenocarcinoma of The Pancreas - Pipeline by GlaxoSmithKline Plc, H1 2016 33
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H1 2016 34
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 35
Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H1 2016 36
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H1 2016 37
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Oncolytics Biotech Inc., H1 2016 38
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Pfizer Inc., H1 2016 39
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Phoenix Biotechnology, Inc., H1 2016 40
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Plexxikon Inc., H1 2016 41
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Sanofi, H1 2016 42
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Targovax AS, H1 2016 43
Assessment by Monotherapy Products, H1 2016 44
Number of Products by Stage and Target, H1 2016 46
Number of Products by Stage and Mechanism of Action, H1 2016 49
Number of Products by Stage and Route of Administration, H1 2016 52
Number of Products by Stage and Molecule Type, H1 2016 54
Metastatic Adenocarcinoma of The Pancreas Therapeutics - Recent Pipeline Updates, H1 2016 141
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H1 2016 219
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H1 2016 220
List of Figures
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H1 2016 11
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Assessment by Monotherapy Products, H1 2016 44
Number of Products by Top 10 Targets, H1 2016 45
Number of Products by Stage and Top 10 Targets, H1 2016 45
Number of Products by Top 10 Mechanism of Actions, H1 2016 48
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 48
Number of Products by Routes of Administration, H1 2016 51
Number of Products by Stage and Routes of Administration, H1 2016 51
Number of Products by Molecule Types, H1 2016 53
Number of Products by Stage and Molecule Types, H1 2016 53
